Is­rael's Te­va puts for­eign­er in line for CEO's job; Ver­tex wins ex­pand­ed la­bel for Ka­ly­de­co

→ Is­rael’s Te­va is re­port­ed­ly tak­ing a hard look at a for­eign­er for its next CEO, spark­ing a pa­tri­ot­ic row.

→ The FDA has ap­proved Ver­tex’s Ka­ly­de­co for use in peo­ple with cys­tic fi­bro­sis (CF) ages 2 and old­er who have one of 23 resid­ual func­tion mu­ta­tions in the cys­tic fi­bro­sis trans­mem­brane con­duc­tance reg­u­la­tor (CFTR) gene. As a re­sult, the Boston biotech bumped up its rev­enue pro­jec­tions for the year to $770 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER